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Abstract. Connexin 43 (Cx43) is the main gap junction protein 
in astrocytes and exerts the same effects on growth inhibition 
in astrocytoma and glioma as microRNA-146a (miR-146a) in 
glioma. β2-adrenergic receptor (AR) signaling modulates Cx43 
expression in myocytes via components downstream of protein 
kinase A (PKA) and exchange protein directly activated by 
cAMP (Epac). However, it remains to be elucidated how expres-
sion of Cx43 is modulated in astrocytes. In the present study, 
1321N1 astrocytoma cells were treated with β2-AR signaling 
agents in order to evaluate the expression of Cx43 and miRNAs. 
RNA and protein were extracted from the cells for use in reverse 
transcription-quantitative polymerase chain reaction and western 
blot analysis, respectively. The results revealed that clenbuterol 
increased miR-146a level and upregulated Cx43 expression via 
cAMP/PKA at the mRNA and protein level. Pre-inhibition of 
adenyl cyclase decreased expression of Cx43 and miR-146a. 
PKA activation and overexpression of miR-146a in A-1321N1 
cells increased the expression of Cx43. β2-AR stimulation 
and 6Bnz, a PKA activator, suppressed oncomiRs miR-155 
and miR-27a, while 8-(4-chlorophenylthio)-2'-O-methyl 
adenosine-3',5'-cyclic monophosphate, an Epac activator, 
increased their levels. The current findings demonstrated that 
β2-AR signaling has growth inhibitory effects via modulation of 
the cAMP/PKA pathway in A-1321N1 cells through increasing 
the expression level of Cx43 and miR-146a as well as decreasing 
miR-155 and miR-27a levels. Thus, stimulation of the β2-AR 
and PKA signaling pathway may be a useful approach for astro-
cytoma therapy.
Introduction
The majority of malignant brain tumors are astrocytoma or 
glioma, which are often fatal with a median survival time from 
diagnosis of ~15 months (1). Connexins (Cxs), particularly 
Cx43 (2) and certain microRNAs (3,4) are important in the 
modulation of astrocytoma and glioma. Since current clinical 
approaches, including surgery, chemotherapy and radiotherapy 
do not have a significant impact on patient survival (5), it is 
crucial to develop new therapeutic methods and drugs for the 
treatment of these diseases. Cx43 is the major Cx in astrocytes 
and is involved in cell cycle regulation and growth modula-
tion (2). Cx43 has inhibitory effects on astrocytoma (6) and 
glioma progression (4). In addition, Cx43 enhances apoptotic 
effects (7-9). Cx43 expression is decreased in astrocytoma and 
glioma (10). In this regard, downregulation and upregulation 
of Cx43 leads to enhanced and decreased development of 
tumor malignancies, respectively (5,11,12).
miRNAs are small, non-coding RNAs of 19-24 nucleotides 
in length that regulate gene expression and are significantly 
associated with either tumor development or suppression (13). 
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miRNAs have been associated with several types of cancer, 
including glioma and its aggressive glioblastoma subtype (14). 
A study concerning the effects of miRNA and Cx43 expres-
sion demonstrated that miR-125b inhibits Cx43 expression and 
increases glioma cell development (15). However, overexpres-
sion of Cx43 inhibits the effects of miR-125b in glioma cell 
improvement and its anti-apoptotic effects (15). β2-adrenergic 
receptor (AR) signaling upregulates Cx43 expression via 
cAMP/protein kinase A (PKA) and cAMP/exchange protein 
directly activated by cAMP (Epac) pathways in myocytes (16). 
The cAMP/PKA pathway markedly activates miR-335, which 
is required for differentiation therapy of C6 glioma cells (17). In 
this cell line, miR-146a is a glioma suppressor candidate (18), 
which has possible associations with β2-AR signaling and 
Cx43 expression. 
The current study aimed to identify the effect of β2-AR 
signaling and the role of its downstream components, adenyl 
cyclase inhibition, PKA activation and Epac on Cx43 expres-
sion in a human-derived astrocytoma cell line (A-1321N1). 
In addition, the effects of miR-146a on the overexpression of 
Cx43 were evaluated. Finally, the effect of the pathways down-
stream of β2-AR signaling (PKA and Epac) on the expression 
of miR-146a were investigated.
Materials and methods
Materials. Clenbuterol hydrochloride (Cln), selective β2 
agonist (C5423), SQ22, 536 (SQ), adenyl cyclase inhibitor 
(ACi, S153), 6-Bnz-cAMP sodium salt (6Bnz), specific 
PKA activator (B4560), 8-(4-chlorophenylthio)-2'-O-meth-
yladenosine‑3',5'‑cyclic monophosphate (8CPT), Epac‑specific 
activator (C8988), Brefeldin (BF) and Epac inhibitor 
(B7651) were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). Antibodies, including mouse monoclonal 
anti-connexin43/GJA1 (1:1,000; cat no. ab79010), mouse 
monoclonal anti-β‑actin (1:5,000; cat no. ab6276), rabbit 
polyclonal secondary antibody to mouse IgG (1:10,000; cat 
no. ab6728) and goat polyclonal secondary antibody to rabbit 
IgG (1:10,000; cat no. ab6721) were all purchased from Abcam 
(Cambridge, MA, USA).
Cell culture and treatment. An A-1321N1 cell line was 
purchased from the National Cell Bank of Iran (Tehran, 
Iran). microRNA-146a (miR-146a) was overexpressed in this 
cell line. The cells were maintained in Dulbecco's modified 
Eagle's medium (DMEM; Gibco-BRL, Carlsbad, CA, USA) 
containing 10% fetal bovine serum (FBS) supplemented with 
50 mg/ml streptomycin and 100 U/ml penicillin (Gibco-BRL) 
in a humidified atmosphere at 37˚C and 5% CO2. Cells in a 
confluent monolayer were routinely passaged by trypsiniza-
tion and the passaged cells were seeded into six-well plates. 
The following day, the DMEM medium, containing 1% FBS, 
was changed prior to drug exposure for 24 h. Subsequently, 
the cells were treated with Cln or 6Bnz for a further 24 h. The 
Cln-treated groups of cells were pretreated in the presence 
or absence of SQ or BF (45 min prior to treatment with Cln) 
for adenyl cyclase and Epac inhibition, respectively. RNA 
and protein extraction were performed for reverse transcrip-
tion-quantitative polymerase chain reaction (RT-qPCR) and 
western blot analysis, respectively.
Virus packaging and transduction. The HEK293T cell line 
was used for virus packaging of PB-miR-146a containing 
green fluorescent protein (GFP) and puromycin resistance 
genes. The cells were maintained in DMEM containing 10% 
FBS supplemented with 50 mg/ml streptomycin and 100 U/ml 
penicillin in a humidified atmosphere at 5% CO2 and 37˚C. A 
Lentivirus packaging system containing the psPAX2 plasmid 
(encoding gag/pol), the pMDG plasmid (encoding VSV-G) 
and PB-miR-146a (as well as empty vector) were used for lenti-
virus production using the calcium-phosphate method (19). 
Subsequently, GFP expression was assessed using an inverted 
fluorescence microscope (Nikon TEF2000; Nikon, Tokyo, 
Japan) following 24 h of transfection. The medium containing 
the produced viruses was collected 24, 48 and 72 h after 
transfection and kept at 4̊C. The medium was subsequently 
concentrated by centrifuging at 40,000 x g at 4̊C for 2.5 h. 
Finally, the two cell lines were infected with the concentrated 
supernatants. At 24 h after transduction, the cells were treated 
with puromycin (2 µg/ml) and this treatment continued for 
3 days. Negative control groups were also treated with puro-
mycin, which, as expected, underwent cell death after 48 h. 
The transfected group (PB-miR-146a) was resistant to puro-
mycin and survived following antibiotic selection (Fig. 1).
Primer design and probe for detecting miRNAs. The sequences 
of miRNAs, including miR-146a, miR-155 and miR-27a were 
obtained from NCBI (http://www.ncbi.nlm.nih.gov/gene). 
Subsequently, an miRNA specific stem-loop primer was 
designed by adding a few complimentary nucleotides from 
the 3' end of the miRNA to the 3' end of the pre-evaluated 
stem-loop construction (20). qPCR was performed with an 
miRNA‑specific forward primer, universal reverse primer and 
specific TaqMan probe.
RNA extraction and RT‑qPCR for mRNA expression. Relative 
quantification of gene expression of various groups of 
A-1321N1 cells was performed. Total RNA was isolated using 
QIAzol lysis reagent (Qiagen, Hilden, Germany) according to 
the manufacturer's instructions and used for cDNA synthesis 
using reverse transcriptase (cat no. RTPL12; Vivantis, 
Oceanside, CA, USA). Specific human primers, including 
GAPDH, Cx43 and cAMP response element-binding protein 
(CREB; Table. I) were used in these experiments with Takara 
SYBR Premix Ex Taq (Takara Bio, Inc., Shiga, Japan). Gene 
expression levels were measured using Rotor-Gene 6000 
(Corbett Life Science, Concorde, NSW, Australia) and the rela-
tive expression ratio of each gene was compared with GAPDH. 
All data were calculated using the relative expression software 
tool (REST 2009.2.0.13; Qiagen).
Analyzing the expression of miRNAs using stem‑loop 
RT‑qPCR. Total miRNAs and specially overexpressed 
miR146a were extracted from A-1321N1 cells by QIAzol 
RNA extraction (Qiagen). For this purpose, the time and 
speed of centrifugation was increased to 15,000 x g for 
15 min to increase the miRNA yield. Finally, extracted 
miRNA was dissolved in RNase-free water and stored 
at ‑80˚C until use. The quality was confirmed using an 
Eppendorf Spectrophotometer (Eppendorf AG, Hamburg, 
Germany). miRNA was extracted from the immortalized cell 
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line or the empty vector (EV) control cells. Subsequently, 
5 µl of extracted miRNA was adjusted to contain no less 
than 5 µg total miRNA and added to 1.5 µl stem-loop RT 
primer (50 nM) and 4 µl distilled water. Reaction samples 
(10.5 µl) were incubated in a Bio-Rad thermal cycler (MJ 
Mini; Bio-Rad, Hercules, CA, USA) at 65˚C for 10 min. The 
samples were kept on ice and 4 µl 5X reverse transcriptase 
buffer (Roche Diagnostics GmbH, Mannheim, Germany), 
2 µl dNTPs (10 mM), 2 µl DTT (10 mM), 1 µl Expand reverse 
transcriptase (50 units; Roche Diagnostics GmbH) and 0.5 µl 
RNase inhibitor (20 units) was added. cDNA synthesis was 
conducted as follows: 25˚C for 15 min, 37˚C for 15 min, 
42˚C for 40 min and finally 95˚C for 2 min to inactivate the 
enzyme.
RT-qPCR was performed in a 12.5 µl PCR mixture volume 
composed of 6.5 µl 2X Maxima® Probe qPCR master mix 
(Fermentas, Vilnius, Lithuania), 0.2 µM of each oligonucle-
otide primer, 0.1 µM probe and 2 µl cDNA. The following 
conditions were used for amplification: Enzyme activation step 
at 95˚C for 10 min and 45 cycles of two thermal amplification 
steps: 94˚C for 10 sec and 60˚C for 40 sec. Single fluorescence 
detection was used in each cycle at the end of the 60˚C step 
(extension phase) to elucidate the positive samples. The speci-
ficity was confirmed using gel electrophoresis. Reactions were 
set up manually. Amplification, data acquisition and analysis 
were performed on the Rotor-Gene 6000 (Corbett Life Science) 
using Rotor-Gene 6.1 and REST software. Samples were 
assessed in triplicate along with pertaining controls, including 
positive, negative, no-template and RT-minus controls. A 
previously approved and non-treated RNA, SNORD 47, was 
used as an internal control (21). The Ct is the fractional cycle 
number at which the fluorescence passes the fixed threshold. 
REST software was used for statistical analysis of relative 
miRNA expression.
Table I. Sequences of human primers.
    Length Conc
Gene Accession number Forward primer Reverse primer (bp) (µM)
Cx43 NM_000165.3 GGATTGTCCTTAAGTCCCTG CACAAGTCCATTGACACCTG 100 0.4
CREB XM_005246324.1 AACCAGCAGAGTGGAGATGCA GGCATAGATACCTGGGCTAATGTG 101 0.4
GAPDH NM_002046 CTCTCTGCTCCTCCTGTTCG ACGACCAAATCCGTTGACTC 114 0.4
Cx43, connexin 43; CREB, cAMP response element-binding protein; bp, base pair; Conc, concentration.
Figure 1. Transfection and transduction. HEK293T cells were transfected with vector PB-miR-146a-eGFP using the calcium-phosphate method. (A and B) Phase 
contrast and fluorescent image of HEK293T cells. Efficient transfection of HEK293T cells was verified by visualizing GFP expression after 24 h, using an 
inverted fluorescence microscope. (C and D) Phase contrast and fluorescent image cells. Virus‑transducted A‑1321N1 cells following puromycin selection. 
Expression of the GFP as a reporter gene was visualized by fluorescent microscopy. GFP, green fluorescent protein. 
  A   B
  C   D
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Western blot analysis. Total cell lysates were prepared 
following harvesting cells in ice-cold phosphate-buffered 
saline (Gibco-BRL) and homogenization in cold lysis buffer 
(RIPA buffer; Gibco-BRL). Protease inhibitor cocktails 
(cat no. S8820; Sigma-Aldrich) were added to the lysis buffer. 
Lysates were centrifuged at 13,680 x g for 10 min and the 
supernatant was transferred to a new tube. Protein content 
was measured using the bicinchoninic acid method (BCA 
protein kit; Pierce Biotechnology, Inc.). Subsequently, equal 
quantities of protein (25 µg) were added to each well in 
12.5% standard SDS-PAGE and a wet transfer was performed 
(Bio-Rad). Proteins were transferred onto polyvinylidene 
difluoride membranes (Gibco-BRL) and membranes were 
blocked with 2% skimmed milk in Tris-buffered saline/Tween 
20 (TBST 20; 0.5%; Gibco-BRL) for 2 h at room temperature. 
Membranes were incubated overnight at 4̊C with primary 
antibodies against Cx43 1:5,000 diluted in TBST (0.5%). 
Membranes were washed three times with TBST 20 and 
subsequently incubated for 1 h at room temperature with the 
corresponding horseradish-peroxidase-conjugated secondary 
antibodies: Rabbit polyclonal secondary antibody to mouse 
IgG. Following three washes with TBST 20 (0.5%), detection 
was conducted by applying Pierce ECL plus western blotting 
substrate (cat no. 32134; Pierce Biotechnology, Inc.), emanating 
chemiluminescence from the membrane for manual x‑ray film 
development. Levels of the analyzed proteins were normalized 
to β-actin levels.
3‑(4,5‑dimethylthiazol‑2‑yl)‑2,5‑diphenyltetrazolium bromide 
(MTT) assay. To evaluate the cytotoxic effect of Cln treatment 
on the A-1321N1 cell line, cell viability was measured using 
the MTT colorimetric assay (Sigma-Aldrich). Cells were 
seeded into 96 well plates at a density of 0.5x104 cells/well 
and left overnight to attach. The following day, the medium 
was changed to a fresh medium containing different concen-
trations of Cln (1, 5, 10, 20 and 40 µg/ml). At 24 h after 
treatment, MTT reagent (5 mg/ml) was added and incubation 
was continued at 37˚C for 3 h. The medium was discarded and 
the formazan crystals were dissolved by adding dimethyl sulf-
oxide (100 µl/well; Gibco-BRL). Finally, the optical density of 
each well was determined using a spectrophotometer (ELx800; 
BioTek Instruments, Inc., Winooski, VT, USA) at a wavelength 
of 570 nm against 630 nm. 
Statistical analysis. The acquired data were analyzed by 
SPSS software 19 (SPSS, Inc., Chicago, IL, USA). P<0.05 
was considered to indicate a statistically significant differ-
ence. Experiments were performed in triplicate and data are 
presented as the mean ± standard error of the means.
Results
Expression of Cx43 by β2‑AR signaling agents. The specificity 
of cAMP signaling on Cx43 expression in astrocytoma cells 
was assessed following 24 h treatment of cells with drugs. 
Cln (10 µg/ml), a selective β2‑AR agonist, led to a significant 
upregulation in Cx43 at the mRNA (Fig. 2; P<0.001) and protein 
levels (Fig. 3; P<0.05). Pretreatment with SQ (50 µg/ml) 45 min 
prior to Cln treatment significantly inhibited Cx43 expression 
at the mRNA (Fig. 2; P<0.001) and protein levels (Fig. 3; 
P<0.05). By contrast, BF (100 µg/ml) administered 45 min 
prior to Cln treatment increased Cx43 expression at the mRNA 
(Fig. 2; P<0.001) and protein level (Fig. 3; P<0.05) compared 
with the Cln alone group. Selective activation of PKA by 6Bnz 
(50 µg/ml) also resulted in significant upregulation of Cx43 at 
the mRNA (Fig. 2) and protein (Fig. 3) level (P<0.001). The 
expression level of Cx43 mRNA was measured in miR-146a 
overexpressing A-1321N1 cells (P<0.001). The results revealed 
that Cx43 was significantly upregulated (Fig. 2; P<0.001) in a 
parallel manner to 6Bnz treatment. Therefore, Cln may upreg-
ulate Cx43 via PKA activation since 6Bnz, a PKA activator, 
upregulated Cx43 expression significantly more than Cln and 
Epac inhibition did not prevent its upregulation.
Expression of CREB. CREB level was measured following 
treatment with different doses of Cln (10 µg/ml) and 
pre-inhibition with SQ (50 µg/ml), ACi and BF (100 µg/ml). 
Cln treatment upregulated CREB levels, while adenyl cyclase 
(P<0.01) and Epac inhibition (P<0.05) downregulated 
CREB levels. CREB levels were measured in the 6Bnz 
Figure 2. Relative mRNA expression of Cx43 in A-1321N1 cells. A-1321N1 
cells were treated with Cln (10 µg/ml), a selective β2 agonist; SQ (50 µg/ml), 
an adenyl cyclase inhibitor + Cln (10 µg/ml); BF (50 µg/ml), an Epac inhib-
itor + Cln and 6Bnz (50 µg/ml), a protein kinase A activator for 24 h and 
the relative mRNA expression of Cx43 was measured. Cx43 was measured 
in miR-146a overexpressing A-1321N1 cells. The results revealed that Cx43 
was significantly upregulated following treatment with Cln (10 µg/ml), BF 
(100 µg/ml) + Cln (10 µg/ml) and 6Bnz (100 µg/ml) in miR-146a overex-
pressing cells. Pretreatment with SQ (50 µg/ml) completely inhibited Cx43 
expression compared with the Cln group, however, Epac inhibition by BF 
(100 µg/ml) increased its expression. Relative expression of each group was 
normalized with GAPDH using a relative expression software tool. Data 
obtained from three independent experiments were analyzed similarly 
to the control group. Bar graphs show the mean ± standard error of the 
mean from at least three individual experiments. **P<0.01, ***P<0.001 and 
###P<0.001, compared with the Cln treated and untreated group. GAPDH was 
used as a control. Cx43, connexin 43; Cln, clenbuterol hydrochloride; 6Bnz, 
6-Bnz-cAMP sodium salt; BF, Brefeldin; SQ, SQ22,536.
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(50 µg/ml)‑treated group, which significantly upregulated 
the level of CREB (P<0.001). Epac inhibition decreased 
CREB level compared with the Cln (P<0.05) and 6Bnz 
(P<0.001) groups, however, its higher expression compared 
with the adenyl cyclase inhibited group was not significant. 
Expression of CREB in miR-146a overexpressing A-1321N1 
cells was measured and the results shown in Fig. 4 demon-
strated that its expression significantly increased compared 
with GAPDH (P<0.001).
Additionally, the mRNA level of Cx43 and CREB in 
miR-146a overexpressing A-1321N1 cells (P<0.001) was 
measured, which demonstrated that Cx43 and CREB were 
significantly upregulated in a parallel manner in miR‑146a 
overexpressing cells (Fig. 5; P<0.001).
Effects of β2‑AR, PKA and Epac activation on miRNA level. 
Fig. 6 shows the miR-146a level in overexpressing astrocytoma 
cells and EV of A‑1321N1 cells. miR‑146a was significantly 
upregulated in overexpressing A-1321N1 cells compared with 
EV cells (P<0.001).
Putative regulation of miR‑146a was verified by stem‑loop 
RT-qPCR after 24 h treatment. Pharmacological intervention 
of the cAMP/PKA pathway with different drugs demonstrated 
that Cln at doses of 10 and 20 µg/ml significantly upregulated 
miR-146a level in A-1321N1 cells (P<0.001). 6Bnz (50 µg/ml), a 
PKA activator, had the same effect as Cln (P<0.001). However, 
8CPT, an Epac activator, (50 µg/ml) downregulated the level 
of miR-146a (P<0.001). Adenyl cyclase (20 µg/ml) inhibition 
eliminated the effect of Cln (10 and 20 µg/ml) on miR-146a 
expression at the two doses (P<0.01). Taken together, the 
results suggested that miR-146a expression was upregulated 
through the cAMP/PKA pathway and was decreased via the 
cAMP-Epac pathways (Fig. 7).
Fig. 8 illustrates pharmacological intervention on miR-146a 
and two oncomiRs, miR-155 and miR-27a. Cln (10 µg/ml) and 
6Bnz (50 µg/ml) significantly upregulated miR‑146a levels, 
Figure 3. Western blotting of the Cx43 protein. The bar graph presents 
the expression level of Cx43 protein following treatment with Cln and 
the cAMP/protein kinase A-Epac signaling pathway in A-1321N1 cells. 
(A) Expression of Cx43 protein in A-1321N1 cells. Cx43 protein level was 
normalized to β-actin. (B) Bar graphs show the mean ± standard error of 
the mean from at least three individual experiments. Cln (10 µg/ml), BF 
(100 µg/ml) + Cln and 6Bnz (100 µg/ml) significantly increased Cx43 
expression compared with the control group. SQ 50 µg/ml significantly 
downregulated Cx43 expression compared with the Cln group. *P<0.05 and 
**P<0.01, compared with the control group. Blots from one representative 
experiment are shown. Cx43, connexin 43; Cln, clenbuterol hydrochloride; 
6Bnz, 6-Bnz-cAMP sodium salt; BF, Brefeldin; SQ, SQ 22,536.
  A
  B
Figure 4. Relative mRNA expression of CREB in A-1321N1 cells. This 
figure presents the relative mRNA expression of CREB in the β2-adrenergic 
receptor signaling pathway. Cln (10 µg/ml) treatment significantly upregu-
lated the mRNA level of CREB compared with GAPDH expression. SQ 
(50 µg/ml) and Brefeldin (100 µg/ml) significantly pre‑inhibited Cln treat-
ment of CREB expression. 6Bnz (50 µg/ml) and the miR-146a overexpressed 
cell group had significantly increased levels of CREB mRNA compared 
with the Cln group. Data obtained from three independent experiments were 
analyzed similarly to the control group. Bar graphs show the mean ± stan-
dard error of the mean from at least three individual experiments. Different 
treatment groups compared with the Cln group and Cln compared with the 
untreated group. *P<0.05, **P<0.01, ***P<0.001 and ###P<0.001, compared 
with the Cln treated and untreated group. GAPDH was used as a control. Cln, 
clenbuterol hydrochloride; CREB, cAMP response element-binding protein; 
SQ, SQ 22,536; 6Bnz, 6-Bnz-cAMP sodium salt.
KHAKSARIAN et al:  CONNEXIN 43 AND microRNA EXPRESSION VIA β2-ADRENOCEPTOR1946
while the level of miR‑155 was significantly downregulated. 
Treatment with Cln (10 µg/ml) and 6Bnz (50 µg/ml) also 
downregulated miR-27a, however, this was not significant. 
Following treatment with the Epac activator, 8CPT (20 µg/ml), 
the levels of miR-155 and miR-27a were upregulated, while 
the levels of miR‑146a were significantly downregulated. By 
contrast, 6Bnz (50 µg/ml) significantly upregulated the level of 
miR-146a. Therefore, β2-AR stimulation and PKA activation 
increased the suppressant miR-146a levels and decreased the 
level of miR-155 and miR-27a oncomiRs, while Epac activa-
tion downregulated miR-146a and upregulated oncomiRs, 
miR-155 and miR-27a.
Cell viability. Different doses of Cln (1, 5, 10, 20 and 40 µg) 
inhibited cell proliferation in a dose-dependent manner 
(Fig. 9). Cln significantly inhibited cell proliferation after 24 
and 48 h compared with the control group.
Expression of Connexin 43 and miRNAs via β2 adrenoceptor 
signaling in A‑1321N1cell. β2 adrenoceptor activation via 
cAMP-PKA pathway upregulated the expression levels of 
Cx43, CREB and miR-146a and downregulated the expression 
of miR-155. By contrast, the β2 adrenoceptor upregulated the 
expression levels of miR-27a and miR-155, and downregulated 
the expression of miR-146a via the cAMP-Epac pathway 
(Fig. 10).
Discussion
Currently, molecular target therapy has become one of the 
most useful strategies for disease treatment (22) and may be a 
promising approach for astrocytoma and glioma therapy (23). 
The findings in the present study exhibit novel Cx43 regulation 
in astrocyte models, that were demonstrated by overexpression 
of miR-146a in the A-1321N1 cell line and β2-AR stimula-
tion in A-1321N1 cells. These results revealed that β2-AR 
Figure 6. miR-146a expression. Expression level of miR-146a in overexpressed 
cells was significantly enhanced compared with empty vector‑transduced astro-
cytoma 1321N1 cells. ***P<0.001, compared with te empty vector-transduced 
astrocytoma 1321N1 cells. Expression level was normalized with SNORD47.
Figure 7. miR-146a expression via β2-AR signaling. β2-AR signaling inter-
vention modulated the relative expression of miR-146a level in astrocytoma 
1321N1. Cln at doses of 10 and 20 µg/ml increased miR-146a level and the 
adenyl cyclase inhibitor, SQ (50 µg/ml), significantly suppressed Cln treat-
ment. 6Bnz (100 µg/ml; protein kinase A activator) and 8CPT (50 µg/ml), an 
Epac activator, significantly increased and decreased miR‑146a expression, 
respectively. Overexpressed miR-146a cells exhibited increased miR-146a 
levels compared with all groups and SNORD47. **P<0.01 and ***P<0.001, 
compared with the untreated cells. Data were normalized to the SNORD47, 
housekeeping gene. Cln, clenbuterol hydrochloride; β2-AR, β2-adrenergic 
receptor; SQ, SQ 22,536; 6Bnz, 6-Bnz-cAMP sodium salt; 8CPT, 
8-(4-chlorophenylthio)-2'-O-methyladenosine-3',5'-cyclic monophosphate.
Figure 5. Relative mRNA expression of Cx43 and CREB in A-1321N1 cells 
and overexpressed miR‑146a in A‑1321N1 cells. The figure presents the 
mRNA level of Cx43 and CREB in astrocytoma 1321N1 cells and overex-
pressing miR-146a 1321N1 astrocytoma cells. Cx43 and CREB expression 
significantly increased their expression in a parallel manner compared with 
GAPDH. ***P<0.001, compared with Cx43 and CREB expression in the 
A-1321N1 cells, which overexpress miR-146a. Cx43, connexin 43; CREB, 
cAMP response element-binding protein.
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activation upregulates the expression of Cx43 in astrocytes via 
a PKA-regulated pathway, possibly involving CREB. In this 
regard, the overexpression of miR-146a is also able to cause 
upregulation of CREB and Cx43 in this cell line, in which 
miR-146a was upregulated by PKA activation. Furthermore, 
β2-AR adrenoceptor signaling activation decreases the 
severity of the glioma as well as decreases the promotion of 
molecules, including miR-155 (24-27) and miR-27a (28,29) 
via its signaling pathway. PKA, activated by 6Bnz, acts as a 
suppressor of the astrocytoma signaling pathway and glioma 
while the Epac signaling pathway, activated by 8CPT acts as a 
modulator. Therefore, β2-AR signaling and particularly PKA 
activation may be useful strategies for astrocytoma and glioma 
therapy. Despite considerable advances in miRNA research, 
there are various obstacles for the use of miRNAs in clinics, 
including miRNA delivery, which prevents the use of miRNAs 
as drugs. Therefore, the drugs that may activate PKA or β2-AR 
signaling have modulating potential on miRNA delivery in 
astrocytoma and Cx43 expression.
In the present study, the effects of β2-AR signaling on Cx43 
expression and its modulating effect on miR-146a level were 
evaluated. In addition, the effects of high levels of miR-146a 
on Cx43 expression were assessed by overexpressing miR-146a 
in A-1321N1 cells. In further investigations, the activation 
of β2-AR signaling was evaluated and the mechanism by 
which PKA and Epac downstream pathways affected the two 
oncomiRs, miR-155 and miR-27a was assessed. The expres-
sion of CREB, a pathway downstream of PKA, in A-1321N1 
cells overexpressing miR-146a and standard A-1321N1 cells 
was also evaluated, which were subject to pharmacological 
intervention. These evaluations revealed that CREB level 
increased in miR-146a overexpressing cells and in cells treated 
with Cln and 6Bnz.
Since the aim of the present study was to demonstrate 
the effects of β2-AR signaling on Cx43 and miR-146a, 
the A-1321N1 cell line, which is a high grade astrocytoma 
model, appropriate for signaling studies was utilized (30). 
miRNA detection was based on the stem-loop method, which 
is recognized for producing high quality data. The current 
results present a method for enhancing the level of miR-146a 
and Cx43 in the astrocytoma cell line via PKA activation and 
β2-AR stimulation.
Higher grade human brain tumors are associated 
with lower adenyl cyclase activity and/or cellular cAMP 
levels (31), in which signaling is modulated by the β2-AR 
signaling pathway (1). cAMP and its associated downstream 
pathways, including 8-Chloro cAMP (17) and PKA (18) 
have been observed to inhibit the proliferation of tumor 
cells (20,23). Additionally, β2-AR knockout astrocytes 
exhibited higher proliferation rates compared with wild-type 
cells (32). Increasing the level of adenyl cyclase activity 
has been associated with decreased glioma cell prolifera-
tion (31). By contrast, Somekawa et al (16) demonstrated that 
PKA activation predominantly contributes to the functional 
neoformation of gap junctions and that Epac is also respon-
sible for gap junction neoformation. In cultured astrocytes, 
Salameh et al (33) demonstrated that PKA and mitogen-acti-
vated protein kinase are involved in Cx43 expression via 
activator protein 1 and CREB through β2-AR stimulation. 
Lu et al (34) demonstrated that β2-AR blockers decreased 
miR-1 level via inhibition of the β2-AR-cAMP-PKA pathway 
in myocytes, which led to downregulation of Cx43 expression. 
In the present study, it was observed that β2-AR stimulation, 
via activation of PKA downstream pathways, upregulated 
the expression of Cx43 and CREB as well as miR-146a 
level in A-1321N1 cells via β2-AR activation. The current 
results implied that β2-AR activation and PKA stimulation 
upregulate Cx43 and CREB expression. Activation of another 
β2-AR downstream pathway, Epac, decreased miR-146a level 
and overexpression of miR-146a had an enhancing effect on 
Figure 8. miRNA expression via protein kinase A and Epac activation. 
The effect of Cln, 6Bnz and 8CPT treatment on the levels of miR-146a, 
miR-155 and miR-27a in 1321N1 astrocytoma cells. Cln (10 µg/ml) and 
6Bnz (50 µg/ml) increased miR‑146a and decreased miR‑155 significantly 
in addition to miR‑27a (not significant), however, 8CPT (20 µg/ml) decreased 
miR-146a and increased miR-155 and miR-27a significantly. Data were 
normalized to SNORD47, a housekeeping miRNA. *P<0.05, **P<0.01 and 
***P<0.001, compared with the untreated cells. Cln, clenbuterol hydrochloride; 
6Bnz, 6-Bnz-cAMP sodium salt; 8CPT, 8-(4-chlorophenylthio)-2'-O-meth-
yladenosine-3',5'-cyclic monophosphate.
Figure 9. Cell viability assessment. Clenbuterol decreased the cell viability of 
A-1321N1 cells in a dose-dependent manner. Different doses of Clenbuterol (1, 
5, 10, 20 and 40 µg) inhibited cell proliferation dose dependently. Clenbuterol 
(40 µg/ml) significantly inhibited the cell viability of 1321N1 astrocytoma 
(24 and 48 h) compared with the control groups (**P<0.01; ***P<0.001). 
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Cx43, which was also demonstrated in the present study. This 
demonstrates that the activation of Epac may negatively effect 
Cx43 expression. In the present study, Epac was deactivated 
in order to analyze its effect on Cx43 expression, which as 
expected, was enhanced. The present study is in accordance 
with other studies regarding Cx43 modulation in astrocytes 
via PKA-CREB activation (33,35). Certain studies have 
revealed that PKA activation in myocytes had weak (16) or 
inhibitory effects (36) on Cx43 expression. Although in these 
studies, miR-1 was investigated in myocytes, which directly 
targets Cx43, whereas in the present study, the microRNA 
investigated (miR-146a) had an indirect role in the upregula-
tion of Cx43 in the A-1321N1 cell line.
Epidermal growth factor (EGF) signals and their down-
stream phosphatidylinositide 3-kinase (PI3K)-Akt pathways 
are established as astrocytoma and glioma promoting 
pathways (18,23,37). Receptor tyrosine kinases (RTKs) 
also possess roles in activation of these pathways (23). Our 
bioinformatics evaluation demonstrated that miR-146a targets 
Epidermal growth factor receptor (EGFR) and RTK signaling 
(unpublished data). In addition, miR-146b inhibits EGFR 
expression and decreases in vitro invasion and migration of 
astrocytoma and glioma cell lines (38). By contrast, there is 
a significant link between the overexpression of EGFR and 
Cx43 downregulation. In rat cortical astrocytes, Cx43 was 
downregulated by EGF signaling stimulation (39). In addition, 
in the present study, it was demonstrated that β2-AR stimula-
tion or PKA activation upregulates miR-146a; therefore, it is 
possible that miR-146a induced the downregulation of Cx43 
via targeting EGFR pathways.
Expression of Cx43 enhanced tumor suppressant func-
tion (37) and anti-proliferative effects on astrocytoma cells. 
Cx43 upregulation and PI3K-Akt pathway inhibition was able 
to modulate the proliferation of astrocytoma cells (38,39). 
Upregulation of miR-155 directly targets Foxo3a (24), 
which inhibits cell-cycle progression at the G1/S transition 
via regulating transcription of the cyclin-dependent kinase 
inhibitor p27 (Kip1), which is recurrently downregulated in 
human glioma (40). In astrocytoma and glioma cells, the level 
of miR-155 is higher than normal, which is known to be an 
oncomiR in glioma development (24,41). Thus, downregula-
tion of miR-155 was able to decrease its inhibitory effect on 
Foxo3a and consequently, Foxo3a inhibits the PI3K-Akt 
pathway and its proliferative effects. It is evident that Epac 
activation may have an opposite role since it was revealed 
in the present study that it downregulates miR-146a and 
upregulates miR-155 levels. Since miR-27a downregulation 
via β2‑AR signaling and the PKA pathway was not signifi-
cant, this suggests that it is not important in A-1321N1 cells. 
miR-155 is elevated in primary and secondary glioblastoma 
and promotes glioma development (41). It has been established 
as one of the prognostic and predictive markers in glioblas-
toma patients (42). The present results indicated that Cln and 
PKA activation decreased miR-155 level and Epac activation 
increased its level. Thus, PKA downregulates miR-155 and 
acts as a tumor suppressant pathway, while Epac increases 
Figure 10. Summary of the expression of connexin 43 and miRNAs via β2‑adrenoceptor signaling. This figure presents a possible pathway of connexin 43 
signaling and tumor-associated miRNA via the β2-adrenoceptor signaling pathway in astrocytoma 1321N1 cells. The effects of miR-146a on Epac expression 
were not evaluated experimentally; however, bioinformatics analysis supported this inhibition (unpublished data). Solid arrows indicate stimulatory effects; 
broken arrows indicate possible stimulatory effects; T-shaped arrows indicate inhibitory effects. CREB, cAMP response element-binding protein; Cx43, 
connexin 43; PKA, protein kinase A.
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miR-155 as a tumor inducer pathway. miR-27a is an oncogenic 
and multidrug resistant miRNA overexpressed in glioma, 
which promotes cell proliferation (28). This microRNA is 
predicted to be involved in glioma progression and initiation 
via different signaling pathways, including adherens junction, 
focal adhesion, the mitogen-activated protein kinase signaling 
pathway, the p53 signaling pathway and the apoptotic signaling 
pathway (29). miR-27a is upregulated by Epac activation, 
however, PKA activation downregulates its level, although 
Cln was not able to significantly alter its levels. miRwalk and 
miRrecords predicted (unpublished data) that miR-155 and 
miR-27a targeted CREB expression. In adipocytes, it is vali-
dated that CREB was targeted by miR-155 induced by tumor 
necrosis factor-α (43). The present study revealed that 6Bnz 
and Cln increased CREB expression, thus, it is possible that 
the downregulation of miR-155 via 6Bnz and Cln increases 
CREB levels and Cx43 expression indirectly.
The studies conducted by Toll et al (1) and Johnstone et al (44) 
support the present results. In these studies, it was suggested 
that cAMP elevation induced by β2-AR agonists has a role 
in antiproliferation and Cx43 in glioma growth inhibition. 
Toll et al (1) demonstrated that cAMP-associated inhibition 
of cell growth in astrocytoma is able to reduce cell growth 
by preventing the growth factor-mediated cell proliferation 
signaling pathways; for instance, extracellular-signal-regu-
lated kinase increases the levels of cell-cycle inhibitor proteins 
p21cip1 and p27kip1 (1). Johnstone et al (44) suggested that 
enhancement of Cx43 expression prolonged mitotic periods 
in order to correspond with a G1 delay in cell cycle, which 
was associated with an enhancement in the expression of the 
cell cycle inhibitor p21cip1 in HeLa-43 and HFF cells (44). 
Huang et al (45) demonstrated that Cx43 acts as a tumor 
suppressor gene, which reduced cell proliferation in vitro and 
in vivo in Cx43-transfected glioma cell lines (45). The present 
study revealed that Cln upregulates Cx43 expression and 
decreases cell viability in a dose-dependent manner and its 
anti-proliferative effect may be associated with Cx43 enhance-
ment.
The current results indicated that β2-AR signaling via the 
downstream cAMP-PKA pathway led to enhanced expres-
sion of Cx43 and miR-146a in A-1321N1 cells. PKA is the 
most important downstream pathway with a potential effect 
on the expression of Cx43 and miR-146a for the treatment of 
astrocytoma and glioblastoma. The current findings suggest 
that the β2-AR pathway results in the upregulation of Cx43, 
CREB and miR-146a via the PKA pathway. By contrast, it 
was demonstrated that miR-146a overexpression may also 
result in upregulation of CREB and Cx43. Furthermore, the 
activation of the PKA pathway caused a downregulation in the 
expression of the miR-155 oncomiR. This demonstrates the 
tumor suppressor role of the PKA pathway. However, the Epac 
pathway decreases the expression of miR-146a, the glioma 
suppressing microRNA, which also possesses a significant 
function in the overexpression of Cx43. The Epac pathway 
also induces the overexpression of miR-155 and miR-27a 
oncomiRs. Overall, the PKA pathway decreased tumor-asso-
ciated features in A‑1321N1 cells. These findings not only 
enhance understanding of certain aspects of the molecular 
biology of astrocytoma and glioma, but may also clarify views 
on new prospective therapeutic and drug targets.
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